Initial results from the KYT program demonstrated that 27% of pancreatic cancer patients harbor highly actionable molecular alterations, defined as biomarkers that predict for a high response rate to appropriately targeted therapies.
ASCO 2019 Poster Presentation Shows Improved Overall Survival for Advanced Pancreatic Cancer Patients Enrolled in the Know Your Tumor Program
AI-enabled precision, speed and scale
Precision oncology and speed to decision, for everyone, at every point of care.
How We Help